

Claims

What is claimed is:

1. A method of treating an *A. baumannii* infection in a subject, the method comprising providing to a subject infected with *A. baumannii* rifabutin and a second antibiotic selected from the group consisting of colistin and cefiderocol.
2. The method of claim 1, wherein the subject is infected with a strain of *A. baumannii* that is resistant to rifabutin.
3. The method of claim 1, wherein the subject is infected with a strain of *A. baumannii* that is resistant to the second antibiotic.
4. The method of claim 1, wherein the second antibiotic is colistin.
5. The method of claim 1, wherein the second antibiotic is cefiderocol.
6. The method of claim 1, wherein the rifabutin is administered intravenously.
7. The method of claim 1, wherein the rifabutin is administered by inhalation.
8. The method of claim 1, wherein the rifabutin and the second antibiotic are provided in a single formulation.
9. The method of claim 1, wherein the rifabutin and the second antibiotic are provided separately.
10. The method of claim 1, wherein the *A. baumannii* comprises a rpoB mutation.
11. A combination therapy comprising rifabutin and a second antibiotic selected from the group consisting of colistin and cefiderocol, wherein the combination therapy comprises

rifabutin and the second antibiotic in a therapeutically effective amount to treat an *A. baumannii* infection in a subject.

12. The combination therapy of claim 11, wherein the subject is infected with a strain of *A. baumannii* that is resistant to rifabutin.
13. The combination therapy of claim 11, wherein the subject is infected with a strain of *A. baumannii* that is resistant to the second antibiotic.
14. The combination therapy of claim 11, wherein the second antibiotic is colistin.
15. The combination therapy of claim 11, wherein the second antibiotic is cefiderocol.
16. The combination therapy of claim 11, wherein the rifabutin is administered intravenously.
17. The combination therapy of claim 11, wherein the rifabutin is administered by inhalation.
18. The combination therapy of claim 11, wherein the rifabutin and the second antibiotic are provided in a single formulation.
19. The combination therapy of claim 11, wherein the rifabutin and the second antibiotic are provided separately.
20. The combination therapy of claim 11, wherein the *A. baumannii* comprises a *rpoB* mutation.